<code id='C897D2B797'></code><style id='C897D2B797'></style>
    • <acronym id='C897D2B797'></acronym>
      <center id='C897D2B797'><center id='C897D2B797'><tfoot id='C897D2B797'></tfoot></center><abbr id='C897D2B797'><dir id='C897D2B797'><tfoot id='C897D2B797'></tfoot><noframes id='C897D2B797'>

    • <optgroup id='C897D2B797'><strike id='C897D2B797'><sup id='C897D2B797'></sup></strike><code id='C897D2B797'></code></optgroup>
        1. <b id='C897D2B797'><label id='C897D2B797'><select id='C897D2B797'><dt id='C897D2B797'><span id='C897D2B797'></span></dt></select></label></b><u id='C897D2B797'></u>
          <i id='C897D2B797'><strike id='C897D2B797'><tt id='C897D2B797'><pre id='C897D2B797'></pre></tt></strike></i>

          Home / entertainment / Wikipedia

          Wikipedia


          Wikipedia

          author:hotspot    Page View:5649
          Dozens of sickle cells in a whirlpool — coverage from STAT
          Adobe

          Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes. 

          The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?

          advertisement

          “We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In